CTLA-4, PD-1, or PD-L1 have shown strong antitumor activity in the experimental animal models and the long-lasting clinical efficacy in cancer patients, such as melanoma, renal cell cancer, and lung cancer (159). This evidence concerns the gene PDCD1 and melanoma.